Lowest Price Guaranteed
Pages
325
Last Updated
January 2026
View Count
23772
The global genome editing market, valued at $4.25 billion in 2025, is projected to reach $5.29 billion in 2026 and $13.36 billion by 2035, representing a CAGR of 10.8% during the forecast period 2026 to 2035.
To learn more about this report, request a free sample copy
The human genome comprises of close to three billion nucleotide base pairs, containing approximately 20,000-25,000 protein-coding regions, or genes. These genes / gene sequences act as a code which regulate or control the synthesis of proteins, hence, controlling gene expression. Recent advances in the field of biotechnology have enabled medical researchers to modify the human genome expression through certain techniques, popularly known as genome editing or genome engineering.
Genome editing or gene editing is a genetic engineering technique that enables the modification (insertion, deletion or replacement) of a single gene or a set of genes within the genome of an organism by altering the nucleotide sequence.
Click On The Thumbnails To View The Full Image
 |
 |
 |
Over the years, the need for genome editing at the desired site in the genome has resulted in the exploration of various genome editing tools that are being developed by gene editing companies; these include zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs) and CRISPR technology. It is worth highlighting that ZFN was the first genetic engineering technique discovered in 1895. This was followed by the development of TALENs in 2011. Thereafter, CRISPR paved its way in this domain.
These gene editing tools have been extensively used as corrective strategies to treat the clinical conditions which develop as a result of genetic abnormalities, such as sickle cell disease, parkinson’s disease, peripheral artery disease, spinal muscular atrophy, autoimmune diseases, and other genetic disorders. Amidst the current initiatives to develop targeted gene edited therapies, gene therapy has emerged as a promising option with an aim to address the underlying genetic cause of a disease by introducing therapeutic genes into cells or by replacing or inactivating faulty / mutated gene.
Click On The Thumbnails To View The Full Image
 |
 |
 |
It is worth mentioning that, as of April 2024, more than 1,100 active clinical trials are evaluating gene therapies across various phases of clinical studies. According to the World Health Organization (WHO), 10 out of every 1,000 individuals are affected by genetic disorders, with over 70 million people worldwide living with such conditions. In fact, more than 40% of infant mortality globally is associated with various genetic disorders.
However, the development of gene edited drug products involves a heavy investment for drug discovery, development, and manufacturing. Therefore, in order to ensure the efficiency, precision and safe delivery of these drugs, pharmaceutical companies have been relying on novel genome editing technologies being developed by genome editing companies. This has urged the companies to integrate advanced technologies, in order to improve the clinical outcome of the therapeutics by achieving the desired genetic manipulation.
Click On The Thumbnails To View The Full Image
 |
 |
 |
The ongoing pace of innovation in this field, along with promising results of cell and gene therapies (developed using genome editing technologies) in clinical trials have emerged as the key drivers for genome editing industry. Additionally, the future of gene editing in agriculture and food security is also another driving factor for the market.
The market report presents an in-depth analysis of the various firms / organizations that are engaged in this market, across different segments, as defined in the below table:
| Key Report Attributes | Details | |
| Forecast Period | Till 2035 | |
| Market Size Current Year | $ 5.29 Billion | |
| Market Size 2035 | $ 13.36 Billion | |
| CAGR (Till 2035) | ~10.8% | |
| Payment Method Employed |
|
|
| Type of Gene Editing Technique |
|
|
| Gene Editing Approach |
|
|
| Gene Delivery Methods |
|
|
| Gene Delivery Modality |
|
|
| Type of Therapy |
|
|
| Application Area |
|
|
| Type of End-User |
|
|
| Key Geographical Regions |
|
|
| Key Companies Profiles |
|
|
| PowerPoint Presentation (Complimentary) |
Available | |
| Customization Scope | 15% Free Customization | |
| Excel Data Packs (Complimentary) |
|
|
One of the key objectives of this market report was to estimate the current genome editing market size, opportunity and the future growth potential over the forecast period. Based on multiple parameters and through primary validations, we have provided an informed estimate on the market evolution during the forecast period, till 2035.
The market report also features the likely distribution of the current and forecasted opportunity across various segments, such as type of payment method employed (upfront payments and milestone payments), type of gene editing technique (CRISPR-Cas system, TALENs, meganucleases, ZFNs and other techniques), gene editing approach (gene knock-out and gene knock-in), type of gene delivery method (ex vivo and in vivo), gene delivery modality (viral vectors and non-viral vectors), type of therapy (cell therapies, gene therapies and other therapies), application area (drug discovery and development, and diagnostics), type of end-user (pharmaceutical and biotechnology companies, and academic and research institutes), key geographical regions (North America, Europe and Asia-Pacific), and leading industry players.
In order to account for future uncertainties and to add robustness to our model, we have provided three genome editing market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.
The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders in the market. In addition, the research report features detailed transcripts of interviews held with the industry stakeholders.
Further, all actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this market report are in USD, unless otherwise specified.
Based on the type of payment method, the market is distributed across upfront payments and milestone payments. Currently, upfront payment segment occupies the majority genome editing market share (53%) in the overall market. This trend is likely to change in the forecast period, with milestone payments generating 62% of the revenue in the coming decade.
Further, the ongoing efforts and increased activity in genome editing domain are likely to translate into great opportunities for firms offering genome editing technologies, since these technologies can generate targeted and efficacious gene-edited drugs with high therapeutic potential. The sustained growth is also expected to result in lucrative monetizing opportunities for technology providers as they compete for a share within the $13.36 billion market (in the form of upfront and milestone payments).
Based on the type of gene editing technique, the global genome editing market is segmented into CRISPR-Cas system, TALENs, meganucleases, ZFNs and other techniques. Presently, the market is dominated by CRISPR-Cas system (84%). This can be attributed to the fact that next-generation CRISPR technologies (base and prime editing) have demonstrated promise in overcoming the limitations associated with conventional gene editing techniques, by offering more customized and precise results. In addition, we have also validated our estimates with stakeholders in this industry. In this context, one of the industry stakeholders mentioned the potential benefits of CRISPR in the genetic testing and detection of diseases, leading to an anticipated decrease in the cost of research and development, thereby increasing its adoption.
Based on the type of gene editing approach, the genome editing industry is segmented into gene knock-out and gene knock-in. The gene knock-out segment occupies the highest share (53%) in the current global market. This can be attributed to the greater feasibility and accessibility of this approach, over the knock-in approach, since knock-in approaches require a complex optimization process.
Based on the type of gene delivery method, the global genome editing market is segmented into ex vivo and in vivo. Currently, the market is dominated by ex vivo delivery methods (62%). This can be attributed to the fact that in ex vivo gene delivery, cells are taken from the patient, modified in the lab, and then reintroduced into the body. This allows precise control over the genetic modification in a lab setting, while minimizing the associated off-target effects. However, in case of in vivo delivery, cell toxicity and target specificity have emerged as major challenges. This is a consequence of the fact that this approach involves direct administration of gene therapy into the patient’s body, which can trigger immune responses, leading to inflammation or rejection.
Based on the type of gene delivery modality, the global genome editing market is segmented into viral vectors and non-viral vectors. Presently, the market is dominated by viral vectors (55%). This trend is likely to change in the upcoming future with non-viral vectors occupying an approximately equal market share (50%). This can be attributed to the various challenges conferred by the usage of viral vectors as gene editing modality, such as immunogenicity, cytotoxicity, carcinogenicity and scale-up issues.
Based on the type of therapy, the global market is segmented into cell therapy, gene therapy and others. The cell therapy segment (65%) occupies the highest genome editing market share. This can be attributed to the wider application of cell therapies in treating a myriad of disease indications, owing to the direct introduction of functional cells into the body to replace damaged ones. On the other hand, gene therapy aims to modify a patient's own cells by introducing new genetic material. Moreover, these therapies are usually developed to treat rare indications.
Further, the higher market share for cell therapies has also been validated from the primary research held with stakeholders in the industry. The inputs suggest that a shift in the market scenario is likely to be observed in the coming decade, with an increasing focus on the use of mRNA-based and CRISPR-based gene therapies, driving the change in this market.
Based on the application area, the global genome editing market is segmented into drug discovery and development, and diagnostics. Presently, drug discovery and development segment occupies the highest market share (85%). This can be attributed to the fact that gene editing technologies, particularly CRISPR, are being widely used for the identification of novel drug targets and understanding the genetic basis of a patient's disease.
Further, based on inputs gathered from primary research, the utilization of genome editing technologies for diagnostics is expected to increase over the years, owing to the potential of these technologies in the early screening / diagnosis of genetic and chronic diseases.
Based on the end-user, the global genome editing market is segmented into pharmaceutical and biotechnology companies, and academic and research institutes. Currently, the pharmaceutical and biotechnology companies segment occupies the highest market share (82%). This is due to the fact that majority of the technology licensing / integration agreements in this domain have been inked with pharmaceutical and biotechnology companies (~90%), thus contributing to majority of the revenues generated by industry players.
This segment highlights the distribution of global genome editing market size across key geographical regions, such as North America (US and Canada), Europe (Germany, France, Ireland) and Asia-Pacific (South Korea, China and Japan). According to our projections, North America is likely to capture the majority (~75%) share of the market, driven by maximum number of technology licensing / integration deals inked by technology providers headquartered in this region. Additionally, North America has received the maximum funding / investment in this domain as compared to other regions.
The “Genome Editing Market (2nd Edition): Industry Trends and Global Forecasts, till 2035” market report features an extensive study of the current market landscape, market size, market forecast and future opportunities for the genome editing technology providers. The market report highlights the efforts of several stakeholders engaged in this rapidly emerging segment of the biotechnology and pharmaceutical industry. Key takeaways of the market report are briefly discussed below.
The market landscape of genome editing companies is concentrated, owing to the presence of over 110 players (very large, large, mid-sized and small companies). Of these, 57% of the companies were established post-2016, indicating significant start-up activity in the genome editing industry. Notable examples of companies (established post- 2021, in alphabetical order) include Akribion Genomics, Cellistic, CorriXR Therapeutics, Couragene, GrittGene Therapeutics, Nephrogen, Nvelop Therapeutics, Primera Therapeutics and SE Therapeutics.
Notably, majority of technologies being developed by players in this domain are based on CRISPR-Cas system (84%). It is worth mentioning that the Nucleofactor technology, developed by Lonza, supports genome editing via TALENs and ZFNs along with CRISPR-Cas System. Further, another technology LUNAR (developed by Arcturus Therapeutics), also supports genome editing via meganucleases, TALEN’s and CRISPR.
In order to optimize the use of their resources and augment their revenue generation opportunities, stakeholders engaged in genome editing market are actively out-licensing their technologies. In this context, it is worth highlighting that 96% of the technology providers have adopted technology out-licensing based business operation model. This can be attributed to the fact that licensing agreements allow companies to mitigate financial and operational risks (associated with the time and capital intensive drug development and commercialization process), by collaborating with established players who already have proven technology, expertise, and regulatory experience.
Several stakeholders have been forging alliances with other industry / non-industry players active in genome editing industry for different purposes, including technology licensing, research and development, product licensing and product development. It is worth highlighting that, since 2018, more than 260 strategic partnerships have been inked by the technology providers in the genome engineering market. It is important to mention that 35% of the partnership agreements inked in 2024 were for technology licensing purposes.
Recent examples include agreements signed between ERS Genomics and Université de Montréal (September 2024), Medicines Discovery Catapult (September 2024), and IRBM (May 2024). With more drug developers licensing their genome editing technologies for evaluation, the market is expected to witness favorable market growth during the forecast period.
A cumulative amount of over USD 14 billion has been raised in the genome editing domain since 2018. This is reflective of the growing interest of companies engaged in the development of gene editing technologies worldwide. It is worth noting that majority of the funds have been raised through venture capital rounds. In terms of the funding amount raised, Intellia Therapeutics raised the maximum funding amount (USD 648.3 million) through secondary offering. Notable examples of funding / investments reported in 2024 include (in reverse chronological order) private placement raised by viTToria Biotherapeutics (November 2024), venture capital raised by Arsenal Bio (September 2024) and grant raised by Bio-Sourcing (September 2024). It is worth mentioning that foreseeing the potential of genome editing technologies, several companies are poised to invest in different funding rounds, thereby propelling the growth of this industry.
Of all the genome editing tools, CRISPR technology, specifically, CRISPR-Cas9 has appeared as the leading genetic engineering technique developed by the stakeholders in the gene editing market. Recently, the domain has witnessed a paradigm shift from conventional CRISPR technology to base editing and prime editing techniques. These novel tools are aimed to improve the long-term safety and efficiency of gene delivery. In this market report, we have captured all the genome editing tools (including CRISPR technology) developed by genome editing companies having application across drug discovery, regenerative medicine and diagnostic applications.
Over the past few years, there has been a steady increase in the genome editing companies offering various gene editing technologies. Of these, majority of the technology providers are based in North America. It is worth noting that North America currently holds the highest market share (~80%) of the genome editing market. A few examples of mid-sized companies based in North America that operate as base editing companies, include Mammoth Biosciences, Metagenomi and Vor Biopharma.
Examples of key companies that are engaged in offering genome editing technologies (arranged in alphabetical order, which have also been profiled in this market report; the complete list of companies is available in the full report) include Arcturus Therapeutics, ArsenalBio, Avectas, Beam Therapeutics, Bio-Sourcing, Caribou Biosciences, Century Therapeutics, CRISPR Therapeutics, Editas Medicine, Flash Biosolutions, Graphite Bio, Intellia Therapeutics, NTrans Technologies, OXGENE, Prime Medicine, Revvity, Vor Biopharma.
This market report includes an easily searchable excel database of all the genome editing companies worldwide that offer gene editing tools.
The market report presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this industry, across different geographies. Amongst other elements, the market research report includes:
Several recent developments have taken place in the field of genome editing. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall trends that have been outlined in our genome editing market analysis.